Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

doi:10.1200/PO-24-00477

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

JCO precision oncology - 1 Oct 2024

Worden Francis P, Pisick Evan, Rothe Michael, Mangat Pam K, Garrett-Mayer Elizabeth, Khalil Maged F, Carrizosa Daniel R, Bauman Jessica R, Leidner Rom S, Duvivier Herbert L, Fu Siqing, Park Min S, Yost Kathleen J, Calfa Carmen J, Marr Alissa S, Balmanoukian Ani S, Behl Deepti, Cannon Timothy L, Nabell Lisle, Powell Steven Francis, Thota Ramya, Hinshaw Dominique C, Gregory Abigail, Grantham Gina N, Halabi Susan, Schilsky Richard L

Abstract excerpt

PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and targetable genomic alterations. Two cohorts of patients with cyclin-dependent kinase inhibitor 2A (CDKN2A)-mutated tumors treated with palbociclib are reported: one with head and neck cancer (HNC) with both squamous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to Head and Neck Neoplasms

Source

Open in PubMed

Identifiers

PMID: 39413339
DOI: 10.1200/PO-24-00477

Genes

HP
CDKN2A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.PMID 39413339Read ↗

Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinomaSemantic proximity Read ↗

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibSemantic proximity Read ↗

Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4/6 Pathway.Semantic proximity Read ↗

Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistanceSemantic proximity Read ↗

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Semantic proximity Read ↗

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancerSemantic proximity Read ↗

Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.Semantic proximity Read ↗

Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.Semantic proximity Read ↗

Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell ResponseSemantic proximity Read ↗

Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.Semantic proximity Read ↗

Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.